A Sit Down With Cancer

Slideshow

A doctor sits down with Cancer to gauge its feelings towards new immunotherapy agents, lower smoking rates, and the US obesity epidemic.

As we bid farewell to last year, let us note that several exciting advances in the treatment of cancer were approved in 2017. New immunotherapy agents with high response rates against recalcitrant tumors led some of us optimistic types to believe that for the first time we might have unearthed the secret to victory. I tried to remain cool and collected while daydreaming about the day when this vile disease is eradicated, but my enthusiasm got the best of me and, like a cheeky reporter, I went so far as to schedule an interview with Cancer, in order to gauge how sanguine it feels about the future. Like Porfiry Petrovitch, the magistrate in Crime and Punishment who questions the murderer Raskolnikov, I sat down with Cancer, ready to interrogate it under the klieg lights. Here are some excerpts from our conversation.Caption/concept by Craig R. Hildreth, MDArtwork by Jon Carter, cartertoons.com

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content